Rapid Nexus | Dr. Margaret Kalmeta, CEO & Founder

Margaret Kalmeta  0:00  
Hi, good afternoon. My name is Dr. Margaret Kalmeta, and I'm the CEO and founder of RapidNexus. The reason that RapidNexus exists is that there are over 1000 amputations every day of diabetic limbs in the US alone. We developed a nanotechnology first of a kind dressing to tackle that problem. And I'll explain as I go along how we do that. Our mission is to give doctors and healthcare professionals the technology that they need to prevent these amputations to close these non healing wounds. We are the only nanotech based wound care technology. We have five issued utility patents national and internationally 17 pending US and international patents. We have FDA registrations and breakthrough designation and progress. The most significant thing is we have statistically significant data that shows us that the market is very segmented. And the wound care that's currently out there tackles problems very well for people in their 40s people in their 50s and younger. However, when you get to the diabetic population into the elderly population, there's a big gap of what's available to help treat them because their limbs are actually devoid of density. And this is what we do we increase the density. So there are 12 million US patients that have slow to non healing wounds. As I mentioned, there were pre pandemic 507 amputations every day. Now there are over 1000 every day diabetic amputations, pre pandemic, the statistics globally were that every 22 seconds someone was receiving an amputation around the globe. The current outcomes are that the healing rate is about 30.5% with current products. As I mentioned, they're designed for different sets of patients. The patients with chronic illnesses, such as diabetes, and other illnesses and aging, they require more. The medical costs per patient is $380,000. And amputation alone is about $125,000, prosthetics up to $100,000 wound care products, and so on this is per patient spend annually in order to prevent these amputations and also in order to treat these patients the healthcare community is spending $350 billion. So this is literally now a pandemic within a pandemic because it's so silent. Why don't we even know about it that there are 1000 patients today that have gotten amputations during the pandemic 40% of those patients being that they are diabetic were afraid to go in to get treatment and so as a result, we have 10 times the amputation rate and 12 times the rate of a major amputation which means the entire limb. So we would like to empower doctors and patients by providing assistance to them that can be used at home via telemedicine. Our pilot studies showed that we are 100% effective to begin closing the wounds and then we are 92% effective in actually closing the wounds. We're also an affordable option. And as I mentioned, we're able to help patients use the system at home. What the system consists of is a nanotechnology wound care dressing. And what it's able to do is it's able to adhere to tissue and actually grow on to the tissue, many layers of it. And the way that this happens is as you know, the skin across the top layer of it contains voltage, our heart runs on voltage, we have salt in our bodies because we need to conduct the voltage. And so this heme is still our X. A system is designed to work with the human body on the electromagnetic principle. The Gen-Ray is used to cover a larger surface area and then we offer other products that help the system work.

And one of them is addressing clear coded dressing that works well with the LED and another one is a very good compression tape that's breathable. We also have are going to, we're including and also including other various massages to help the clinician avoid tiredness, how it works, we put the Hemastyl R on and the wound dressing and then the LED. And together the system closes the wounds for us. This is an example here of a diabetic toe that was diagnosed to be amputated, pardon me for the graphic image. And we treated this toe successfully within two visits 45 minutes each. The patient at the bottom was suffering from a burn wound and for eight years, she has been walking around with this type of open wound. And the only solution for her was that every week she was being scraped, in order to prevent an infection and therefore prevent the amputation. We were able to close this within five weeks. The products, as I mentioned, are really based for another type of population, our, you know, population base of patients have a lot more comorbidities, they're living longer. And so really, they're we fit into a category that has not been innovated into. In other words, we fit into the pre amputation category. This is where we plan to help patients and of course, the easy to heal wounds as well. We are in the business of helping patients $50 billion market the wound care industry market products are $50 billion being spent annually on these products. It's a 25 billion market overall. We are going to market using compounding pharmacies as a market entry. We find that pharmacists already are compounding products because this is such a high unmet medical need. They're already compounding products. And so we made a partnership, we're providing to them our product and the end users, the wound care clinics and the physicians are after our survey, we learned are excited to use us. And basically our milestones are that in 2016, I transferred this technology from the Oral Surgery space where I was growing bone. And I met a gentleman who lost all of his limbs due to amputations. And so therefore, I decided to transfer this technology because people are actually dying here and nobody was dying, if they didn't have bone in their jaw. And our team, I'm Dr. Margaret Kalmeta. And serving as a chief executive officer right now. I'm the founder and oral surgery is my background. I've been able to grow practices and I have five exits within practices. Christine Pasciak Is my co founder and COO and she has she's responsible for the supply chain in the manufacturing. So this was an incredible journey for us. We just finished all of that and we pack we're in the process of packaging it all up. David Kowalski, our board member CEO of many nursing homes, hospitals, and even banks and so helping us gain contracts. And John Wetherall, our board member who wrote our IP and he wrote the IP for the Cystic Fibrosis Foundation. And also did a worldwide royalty sale for Lyrica for 700 million. The Cystic Fibrosis Foundation just sold their IP for 3 billion. So we're very, very happy to come on to the market and the rest of it is too much detail. Thank you very much. We're raising actually series a 10 million for for the warehouse, build up of our product and for marketing to get the product out there into clinicians. Thank you